Lupin has got the US health regulator’s final approval from  for marketing cevimeline hydrochloride capsules that are used in treating the symptoms of dry mouth in patients with Sjogren’s syndrome in the US market.

It has said in a BSE filing that the company has received final approval from the United States Food and Drug Administration (USFDA) to market its cevimeline hydrochloride capsules 30 mg.

It added that the company’s product is a generic version of Daiichi Sankyo Inc’s Evoxac capsules.

Read EquityPandit’s Nifty Pharma Outlook for this week